REG - Venture Life Group - Trading update

Venture LifeAnnouncement

09/06/2020 07:01

RNS Number : 3225P
  
Venture Life Group PLC
  
09 June 2020
  
 

9 June 2020
Venture Life Group plc
("Venture Life" the "Company" or the "Group")
Trading update
Since the start of the year, Venture Life has made various announcements providing updates on the positive trading that the Company achieved. These have included an order book significantly ahead of that at the same time last year and the signing of an exclusive €168 million agreement with the Company's existing Chinese partner for a number of its products, one of which is Dentyl, with orders in excess of €7 million for delivery in 2020. At the same time, all other areas of the business have traded well and the Company's hand sanitising gel brand (DISINPLUSÔ) is seeing good demand. 
In addition, the Company is pleased to announce that it has extended its commercial relationship with Alliance Pharma and has been appointed as a second manufacturer of Alliance's Kelo-Cote products. This is an extension in scope to the existing commercial arrangement between the two companies, which currently runs until the end of 2026. 
Taking these positive developments together, the Company is pleased to announce that it is confident that it will comfortably exceed market expectations for this year. 
This announcement contains inside information.
Jerry Randall, CEO of Venture Life said, "I am proud of how the Company has operated through a challenging period and am delighted with our performance this year. I must pay tribute to the dedication of all our employees in the Group, especially those based at Biokosmes in Northern Lombardy, who have not only kept our business operating in very difficult circumstances, but have also continued to grow the business and bring more opportunities into the Group.
"I am also delighted that the team at Alliance have again extended their business relationship with us, and with the confidence and trust they have in us as one of their key strategic suppliers. Biokosmes has been manufacturing products that sit within the Alliance portfolio since 2001, and Alliance are an extremely valued customer of the Venture Life Group."
For further information, please contact:




Venture Life Group PLC


+44 (0) 1344 578004




Jerry Randall, Chief Executive Officer

Andrew Waters, Chief Financial Officer


 




 
Cenkos Securities plc (Nomad and Broker)


 
+44 (0) 20 7397 8900




Stephen Keys / Mark Connelly / Cameron MacRitchie (Corporate Finance)


 




Russell Kerr / Michael Johnson (Sales)


 




 


 


 




 
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands, these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies for consumer healthcare products, primarily medical devices.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
TSTFLFSTRVITIII